Patient-reported outcomes and neurotoxicity markers in patients treated with bispecific LV20.19 CAR T cell therapy
Jennifer M. Knight(Medical College of Wisconsin), Nirav N. Shah(Medical College of Wisconsin), Rachel Cusatis(Medical College of Wisconsin), Steve W. Cole(APLA Health), Sharon Yim(Medical College of Wisconsin), Anikó Szabó(University of Wisconsin–Madison), Igli Arapi(Medical College of Wisconsin), Parameswaran Hari(Medical College of Wisconsin), Edward Hackett(Medical College of Wisconsin), Garrett Sauber(Medical College of Wisconsin), Cecilia J. Hillard(Medical College of Wisconsin), Ruizhe Wu(Medical College of Wisconsin), Amanda Emmrich(Medical College of Wisconsin), Bryon D. Johnson(Medical College of Wisconsin), Dina Schneider(Lentigen Technology (United States)), Boro Dropulić(Heat Biologics (United States))
Cited by 16
Related Papers
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.1k
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
|The Lancet|2021|456
Circulating Endocannabinoids: From Whence Do They Come and Where are They Going?
|Neuropsychopharmacology|2017|450
Human Social Genomics
|PLoS Genetics|2014|411